'Charm alternative' presentation slideshows

Charm alternative - PowerPoint PPT Presentation

Zofia Oko-Sarnowska Department of Clinical Pharmacology

Zofia Oko-Sarnowska Department of Clinical Pharmacology

Recommendations for the pharmacological treatment of atherosclerotic cardiovascular disease based on clinical trials. Zofia Oko-Sarnowska Department of Clinical Pharmacology. Chronic(stable)plaque Little lipide core Thick fibrous cap A low inflammatory cells migration A low MMP content.

★ ★ ★ ★ ★

1.02k views • 81 slides
C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity

C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity

CHARM. C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity. On behalf of the CHARM Programme Investigators and Committees. Background (1). ACE inhibitors, beta-blockers and spironolactone have been demonstrated to be life-saving in patients with CHF

★ ★ ★ ★ ★

774 views • 67 slides
C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity

C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity

CHARM. C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity. On behalf of the CHARM Programme Investigators and Committees. Background (1). ACE inhibitors, beta-blockers and spironolactone have been demonstrated to be life-saving in patients with CHF

★ ★ ★ ★ ★

812 views • 67 slides
C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity

C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity

CHARM. C andesartan in H eart failure A ssessment of R eduction in M ortality and morbidity. On behalf of the CHARM Programme Investigators and Committees. Background (1). ACE inhibitors, beta-blockers and spironolactone have been demonstrated to be life-saving in patients with CHF

★ ★ ★ ★ ★

676 views • 67 slides
Candesartan in Heart Failure

Candesartan in Heart Failure

CHARM Trial. Candesartan in Heart Failure. Presented at European Society of Cardiology 2003. CHARM Trial. 7,601 patients with heart failure 3 Individual component randomized trials with the ARB candesartan (4 or 8 mg/day, titrated to target dose of 32 mg) or placebo. CHARM Preserved

★ ★ ★ ★ ★

388 views • 8 slides

View Charm alternative PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Charm alternative PowerPoint presentations. You can view or download Charm alternative presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.